The logo of Spanish pharmaceutical company Rovi, in charge of the final ‘fill and finish’ stage of manufacturing Moderna’s COVID-19 vaccine, is seen outside their laboratory in San Sebastian de los Reyes, Spain, November 17, 2020. REUTERS/Marco Trujillo

MADRID, Feb 23 (Reuters) – Spanish pharmaceuticals group Rovi (ROVI.MC) raised its 2022 revenue forecast by posting a 151% jump in annual net profit on Wednesday, citing strong growth in manufacturing under contract and pharmaceutical specialties.

The company said it expects operating revenue growth of between 15% and 20% this year, up from a previous single-digit growth forecast.

Net profit jumped to 153.1 million euros ($173.36 million) in 2021 from 61.1 million euros, while operating income jumped 54% to 648.7 million, the company said.

The Madrid-based group, which has a partnership with Moderna (MRNA.O) to manufacture the COVID-19 vaccine, recently extended its contract with the US drugmaker to produce future drugs based on similar mRNA technology.

Calling the 2021 results “historic,” CEO Juan Lopez-Belmonte Encina forecast continued growth in specialty pharma and underscored the potential of the deal with Moderna.

“At the same time, we are confident in the potential of our current pipeline of R&D projects…because we believe they will drive the company’s growth in the future,” he said. declared.

($1 = 0.8832 euros)

Reporting by Nathan Allen; edited by Jason Neely

Our standards: The Thomson Reuters Trust Principles.